title: The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human.
abstract: OBJECTIVE
  The purpose of this study was to test the hypothesis that infusion of the oxytocin antagonist atosiban results in decreased preterm uterine activity in the human.
  
  
  METHODS
  A randomized, double-blind, placebo-controlled trial was performed. One hundred twenty women from 20 to 36 weeks' gestation with a complaint of labor who had more than four uterine contractions per hour after intravenous hydration but no evidence of cervical changes were randomized to receive a 2-hour intravenous infusion of atosiban at a rate of 300 micrograms/min or placebo. Ond hundred-twelve subjects (56 in each arm) were suitable for analysis of efficacy. Both groups remained at bed rest and received hydration.
  
  
  RESULTS
  The mean percent decrease in contraction frequency was greater in atosiban subjects compared with controls (55.3% +/- 36.3% vs 26.7% +/- 40.4%, mean +/- SD, p < 0.001). A minimal (< 20%) decrease or an increase in contraction frequency was noted in 25 placebo subjects (45%) and seven atosiban subjects (13%). There was no clinically or statistically significant change in maternal blood pressure or heart rate during the infusion. The only adverse experiences possibly related to the drug were nausea and vomiting in one atosiban patient.
  
  
  CONCLUSIONS
  A 2-hour infusion of the oxytocin antagonist atosiban resulted in a significantly greater decline in contraction frequency compared with controls. Oxytocin appears to play a role in the maintenance of preterm uterine activity in the human.
authors.affiliation: University of Southern California, Los Angeles.
authors.forename: T M
authors.initials: TM
authors.lastname: Goodwin
authors.forename: R
authors.initials: R
authors.lastname: Paul
authors.forename: H
authors.initials: H
authors.lastname: Silver
authors.forename: W
authors.initials: W
authors.lastname: Spellacy
authors.forename: M
authors.initials: M
authors.lastname: Parsons
authors.forename: R
authors.initials: R
authors.lastname: Chez
authors.forename: R
authors.initials: R
authors.lastname: Hayashi
authors.forename: G
authors.initials: G
authors.lastname: Valenzuela
authors.forename: G W
authors.initials: GW
authors.lastname: Creasy
authors.forename: R
authors.initials: R
authors.lastname: Merriman
mesh_terms: D000328:Adult; D001510:Bed Rest; D004311:Double-Blind Method; D005260:Female; D005440:Fluid Therapy; D005865:Gestational Age; D006801:Humans; D007752:Obstetric Labor, Premature / Q000188:drug therapy* / Q000628:therapy; D010121:Oxytocin / Q000037:antagonists & inhibitors*; D011247:Pregnancy; D011256:Pregnancy Outcome; D015149:Tocolytic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014590:Uterine Contraction / Q000187:drug effects*; D014668:Vasotocin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D015149:Tocolytic Agents; C047046:atosiban; D010121:Oxytocin; D014668:Vasotocin